Acta Crystallographica Section E

## Structure Reports

Online
ISSN 1600-5368

## Yan Zhan and Shu-Kun Lin*

Department of Chemistry, Fuzhou University, Fuzhou, Fujian 350002, People's Republic of China

Correspondence e-mail: Isk195625@fzu.edu.cn

## Key indicators

Single-crystal X-ray study
$T=293 \mathrm{~K}$
Mean $\sigma(\mathrm{C}-\mathrm{C})=0.002 \AA$
$R$ factor $=0.040$
$w R$ factor $=0.120$
Data-to-parameter ratio $=14.5$
For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

[^0]
## $N^{\prime}$-(2-Hydroxybenzoyl)-2-oxo-2H-chromene-3-carbohydrazide

The coumarin system and the 2-hydroxybenzoyl group in the title compound, $\mathrm{C}_{17} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{5}$, are approximately coplanar. There are some intermolecular $\mathrm{O}-\mathrm{H} \cdots \mathrm{O}$ hydrogen bonds and intramolecular $\mathrm{N}-\mathrm{H} \cdots \mathrm{O}$ hydrogen bonds; the intermolecular $\mathrm{O}-\mathrm{H} \cdots \mathrm{O}$ hydrogen bonds result in a chain along the $a$ axis.

## Comment

Recently, coumarin derivatives have attracted increasing attention due to their remarkable biological properties (Feurer, 1974; Budzisz et al., 2004). Such derivatives represent a class of organic compounds which have extensive and diverse applications (Krasovitskii, 1988; Guilardi et al., 2002). These compounds can exhibit anti-inflammatory activity (Adam et al., 2005), and have been described as agents with potential for anticancer (Georgieva et al., 2004) and anticoagulant activity (Creaven et al., 2005). We present here the crystal structure of the title compound, (I).

(I)

The molecular structure of (I) is shown in Fig. 1. The coumarin system ( $\mathrm{C} 2-\mathrm{C} 10 / \mathrm{O} 1 / \mathrm{O} 2$ ) of the molecule is planar. The dihedral angle between the benzene ring C5-C10 and the fused pyrone ring in the coumarin system is $1.05(8)^{\circ}$. The


Figure 1
The molecular structure of (I), showing the atom-numbering scheme and $50 \%$ probability displacement ellipsoids. The intramolecular hydrogen bonds are shown as dashed lines.
average deviation of these atoms from the mean plane of the coumarin system is 0.015 (1) $\AA$; this value is in agreement with those found in analogous coumarin derivatives (Dobson \& Gerkin, 1996; Kokila et al., 1996). The whole molecule is nearly planar. The dihedral angle between the coumarin system and the 2-hydroxybenzohydrazide unit is 0.67 (5) $\AA$.

The hydrogen bonds are listed in Table 1. There are two intramolecular $\mathrm{N}-\mathrm{H} \cdots \mathrm{O}$ hydrogen bonds and one intermolecular $\mathrm{O}-\mathrm{H} \cdots \mathrm{O}$ hydrogen bond in the crystal structure; the intermolecular hydrogen bond $\mathrm{O} 5-\mathrm{H} 5 \mathrm{O} \cdots \mathrm{O} 4$ links neighbouring molecules, forming a chain (Fig. 2).

## Experimental

All chemicals used in this work were of analytical grade available commercially. The title compound was prepared by reacting ethyl coumarin-3-carboxylate with an equivalent amount of 2-hydroxybenzohydrazide ethanol solution by refluxing for 3 h , resulting in a yellow powder. This was dissolved in ethanol and kept at room temperature for several days to obtain yellow single crystals of (I).

## Crystal data

| $\mathrm{C}_{17} \mathrm{H}_{12} \mathrm{~N}_{2} \mathrm{O}_{5}$ | $Z=4$ |
| :--- | :--- |
| $M_{r}=324.29$ | $D_{x}=1.485 \mathrm{Mg} \mathrm{m}^{-3}$ |
| Monoclinic, $P 2_{2_{1}} / c$ | Mo $K \alpha$ radiation |
| $a=9.467(4) \AA$ |  |
| $b=11.766(4) \AA$ | $\mu=0.11 \mathrm{~mm}^{-1}$ |
| $c=13.268(7) \AA$ | $T=293(2) \mathrm{K}$ |
| $\beta=100.96(2)^{\circ}$ | Block, yellow |
| $V=1$ | $0.60 \times 0.25 \times 0.15 \mathrm{~mm}$ |

$\beta=100.96$ (2) ${ }^{\circ}$
$V=1450.9(11) \AA^{3}$

## Data collection

Rigaku Weissenberg IP
diffractometer
$\omega$ scans
Absorption correction: none
14024 measured reflections

## Refinement

```
Refinement on \(F^{2}\)
\(R\left[F^{2}>2 \sigma\left(F^{2}\right)\right]=0.040\)
\(w R\left(F^{2}\right)=0.120\)
\(S=1.07\)
3321 reflections
229 parameters
```

H atoms treated by a mixture of independent and constrained refinement
$w=1 /\left[\sigma^{2}\left(F_{\mathrm{o}}{ }^{2}\right)+(0.0742 P)^{2}\right]$
where $P=\left(F_{\mathrm{o}}{ }^{2}+2 F_{\mathrm{c}}{ }^{2}\right) / 3$
$(\Delta / \sigma)_{\max }<0.001$
$\Delta \rho_{\text {max }}=0.21 \mathrm{e}^{-3}$
$\Delta \rho_{\min }=-0.25 \mathrm{e}^{-3}$

Table 1
Hydrogen-bond geometry ( $\AA,{ }^{\circ}$ ).

| $D-\mathrm{H} \cdots A$ | $D-\mathrm{H}$ | $\mathrm{H} \cdots A$ | $D \cdots A$ | $D-\mathrm{H} \cdots A$ |
| :--- | :--- | :--- | :--- | :--- |
| O5-H5O $\cdots$ O4 ${ }^{\mathrm{i}}$ | 0.91 | 1.75 | $2.6527(15)$ | 174 |
| N1-H1N $\cdots \mathrm{O} 2$ | 0.93 | 1.90 | $2.6392(15)$ | 134 |
| N2-H2N $\cdots \mathrm{O} 5$ | 0.85 | 1.98 | $2.6135(15)$ | 131 |

Symmetry code: (i) $-x+1, y-\frac{1}{2},-z+\frac{3}{2}$.


Figure 2
A packing diagram for the title compound. Dashed lines represent hydrogen bonds.

All H atoms were located in difference Fourier maps. Those bonded to N and O atoms were refined as riding in their as-found relative positions, giving bond lengths shown in Table 1. Those bonded to C atoms were idealized, with $\mathrm{C}-\mathrm{H}=0.93 \AA . U_{\text {iso }}$ values of all H atoms were refined freely.

Data collection: TEXRAY (Molecular Structure Corporation, 1999) ; cell refinement: TEXRAY; data reduction: TEXSAN; program(s) used to solve structure: SHELXS97 (Sheldrick, 1997); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: ORTEX (McArdle, 1995); software used to prepare material for publication: SHELXL97.

The authors are grateful for financial support from the National Natural Science Foundation of China (grant Nos. 20431010 and 20171012).

## References

Adam, B. S., Pentz, R., Siegers, C. P., Strubelt, O. \& Tegtmeier, M. (2005). Phytomedicine, 12, 52-61.
Budzisz, E., Keppler, B. K., Giester, G., Wozniczka, M., Kufelnicki, A. \& Nawrot, B. (2004). Eur. J. Chem. pp. 4412-4419.
Creaven, B. S., Egan, D. A., Kavanagh, K., McCann, M., Mahon, M., Noble, A., Thati, B. \& Walsh, M. (2005). Polyhedron, 24, 949-957.
Dobson, A. J. \& Gerkin, R. E. (1996). Acta Cryst. C52, 3081-3083.
Feurer, G. (1974). Progress in Medical Chemistry, Vol. 10, edited by G. P. Ellis \& G. B. West, pp. 85-158. London: North Holland.
Georgieva, I., Mihaylov, T., Bauer, G. \& Trendafilova, N. (2004). Chem. Phys. 300, 119-131.
Guilardi, S., da Machado, A. E. H., Resende, J. A. L. C. \& de Franca, E. F. (2002). Acta Cryst. E58, o985-o987.

Kokila, M. K., Puttaraja, Kulkarni, M. V. \& Shivaprakash, N. C. (1996). Acta Cryst. C52, 2078-2081.
Krasovitskii, B. M. (1988). Organic Luminescent Materials, edited by B. M. Krasovitskii \& B. M. Bolotin, ch. 7. Weinheim: VCH.
McArdle, P. (1995). J. Appl. Cryst. 28, 65.
Molecular Structure Corporation (1999). TEXRAY and TEXSAN. Versions 1.10. MSC, 9009 New Trails Drive, The Woodlands, TX 77381-5209, USA.

Sheldrick, G. M. (1997). SHELXL97 and SHELXS97. University of Göttingen, Germany.


[^0]:    (C) 2006 International Union of Crystallography All rights reserved

